Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.690
+0.020 (0.54%)
At close: Apr 28, 2026, 4:00 PM EDT
3.690
0.00 (0.00%)
After-hours: Apr 28, 2026, 7:05 PM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 7.56, with a low estimate of 4.25 and a high estimate of 11. The average target predicts an increase of 104.88% from the current stock price of 3.69.
Analyst Consensus: Buy
* Price targets were last updated on Mar 12, 2026.
Analyst Ratings
The average analyst rating for Prime Medicine stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $11 | Buy | Initiates | $11 | +198.10% | Mar 12, 2026 |
| Citigroup | Citigroup | Hold Maintains $5 → $4.25 | Hold | Maintains | $5 → $4.25 | +15.18% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +143.90% | Nov 10, 2025 |
| Citigroup | Citigroup | Hold Maintains $1.5 → $4 | Hold | Maintains | $1.5 → $4 | +8.40% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +171.00% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
4.96M
from 4.63M
Increased by 7.06%
Revenue Next Year
7.29M
from 4.96M
Increased by 47.01%
EPS This Year
-0.94
from -1.35
EPS Next Year
-0.91
from -0.94
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.5M | 23.1M | ||||||
| Avg | 5.0M | 7.3M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 126.7% | 365.8% | ||||||
| Avg | 7.1% | 47.0% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.72 | -0.45 | ||||||
| Avg | -0.94 | -0.91 | ||||||
| Low | -1.16 | -1.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.